Trial Profile
Blood Brain Barrier permeability predicts treatment response in Multiple Scerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2018
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 05 Apr 2018 New trial record
- 31 Mar 2018 Results published in the Annals of Neurology